<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00742599</url>
  </required_header>
  <id_info>
    <org_study_id>NPO-11-01/C-01</org_study_id>
    <nct_id>NCT00742599</nct_id>
  </id_info>
  <brief_title>Phase III Controlled Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy</brief_title>
  <official_title>Phase III Controlled Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy (Randomized, Double-blind, Parallel-assignment , Placebo-controlled Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nihon Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nihon Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who require gastric endoscopy will receive an intragastric single dose of NPO-11 20&#xD;
      mL. The superiority of NPO-11 to placebo as a premedication for endoscopy will be verified in&#xD;
      a randomized, double-blind, parallel-assignment design based on the percentage of patients&#xD;
      having no gastric peristalsis at both 2 minutes post-dose and the end of endoscopy (primary&#xD;
      outcome measure).&#xD;
&#xD;
      The safety of NPO-11 will be evaluated based on adverse events and adverse drug reactions&#xD;
      (ADRs) observed between administration and seven days after administration in comparison with&#xD;
      the placebo group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence or absence of gastric peristalsis (central evaluation by independent evaluator) No gastric peristalsis is defined as when patients have no gastric peristalsis at both 2 minutes post-dose and the end of endoscopy.</measure>
    <time_frame>each evaluation point</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in gastric peristalsis</measure>
    <time_frame>each evaluation point</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difficulty level of intragastric observation (evaluation by investigator who performs endoscopy)</measure>
    <time_frame>each evaluation point</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events and ADRs observed between administration and 7Â±3 days after administration</measure>
    <time_frame>each evaluation point</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Patients Undergoing Gastric Endoscopy</condition>
  <arm_group>
    <arm_group_label>N</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPO-11</intervention_name>
    <description>20 ml NPO-11</description>
    <arm_group_label>N</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>20 ml NPO-11(Placebo)</description>
    <arm_group_label>P</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inpatients or outpatients of either sex who visit medical institutions for treatment or&#xD;
        follow-up of confirmed or suspected upper gastrointestinal disease (symptoms) and meet the&#xD;
        criteria (1) and (2) below will be enrolled in the study. Patients have to provide written&#xD;
        informed consent for voluntary participation in the study.&#xD;
&#xD;
          1. Patients who need gastric endoscopy (except for endoscopy with a scope of &lt;9 mm in&#xD;
             diameter, emergency endoscopy and endoscopy for comprehensive medical examination)&#xD;
&#xD;
          2. Patients who are older than 20 years at the time of consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients who meet any of the following criteria will be excluded from the study. The&#xD;
        criteria (2) to (5) will be confirmed during endoscopy. Patients who meet any of these&#xD;
        criteria will be withdrawn from the study at the time of confirmation.&#xD;
&#xD;
          1. Patients with a history of surgery to the upper gastrointestinal tract&#xD;
&#xD;
          2. Patients with severe gastric stenosis or deformation which makes observation of&#xD;
             gastric peristalsis difficult&#xD;
&#xD;
          3. Patients with upper gastrointestinal bleeding which requires hemostasis&#xD;
&#xD;
          4. Patients with reflux esophagitis (Los Angeles classification: B, C or D)&#xD;
&#xD;
          5. Patients with gastric or duodenal ulcers in active stage&#xD;
&#xD;
          6. Patients on cancer treatment (chemotherapy or radiotherapy)&#xD;
&#xD;
          7. Patients with impaired cardiac function (NYHA functional classification: III or IV)&#xD;
&#xD;
          8. Patients with a history of shock or hypersensitivity to l-menthol or peppermint oil&#xD;
             (mint oil)&#xD;
&#xD;
          9. Patients with a history of shock or hypersensitivity to lidocaine hydrochloride&#xD;
&#xD;
         10. Pregnant or lactating women, women of childbearing potential, or women who plan to&#xD;
             become pregnant during the study&#xD;
&#xD;
         11. Patients who have been exposed to NPO-11&#xD;
&#xD;
         12. Patients who have received other investigational drugs within four months before&#xD;
             consent or who are participating in other clinical studies&#xD;
&#xD;
         13. Patients otherwise ineligible for participation in the study in the investigator's or&#xD;
             subinvestigator's opinion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Kansai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <study_first_submitted>August 25, 2008</study_first_submitted>
  <study_first_submitted_qc>August 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2008</study_first_posted>
  <last_update_submitted>November 8, 2010</last_update_submitted>
  <last_update_submitted_qc>November 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Yasumasa Ogawa</name_title>
    <organization>Nihon Pharmaceutical Co., Ltd</organization>
  </responsible_party>
  <keyword>Stomach Diseases</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

